Used in targeted cancer therapies, particularly for tumors overexpressing FGFR3, such as certain bladder, cervical, and multiple myeloma cancers. Acts as a monoclonal antibody that binds specifically to FGFR3 (CD333), blocking receptor signaling involved in cell proliferation and survival. This inhibition suppresses tumor growth and can induce apoptosis in cancer cells. Also serves as a reference standard in immunoassays and drug development for evaluating the binding affinity and efficacy of experimental anti-FGFR3 agents. Investigated in combination with other immunotherapies to enhance anti-tumor immune responses.